Discover 779 paid clinical trials in Buffalo, New York. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 779
Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia
for
Hypercholesterolemia, Hypertriglyceridemia,
Location: Toronto, Montreal, Chicoutimi, New York NY,
Sponsor: Verve Therapeutics, Inc.
Sex: All
Age: 18 - 70
Code: NCT06451770
Phase 1, Recruiting
Featured
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
for
Multiple Myeloma
Location: Toronto, New Brunswick NJ, New York NY, Montreal,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT06896916
Phase 1, Recruiting
Active & Responsive
A Study of YL201 in Patients With Advanced Solid Tumors
for
Advanced Solid Tumor
Location: Toronto, Brampton, Detroit MI, Ann Arbor MI,
Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
Sex: All
Age: 18+
Code: NCT05434234
Phase 1, Phase 2, Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
for
Chronic Obstructive Pulmonary Disease
Location: Buffalo NY, Niagara Falls, Windsor, Detroit MI,
Sponsor: Sanofi
Sex: All
Age: 40 - 70+
Code: NCT07190222
Phase 3, Recruiting
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
for
Type 1 Diabetes Mellitus
Location: Buffalo NY, Ottawa, Ann Arbor MI, Philadelphia PA,
Sponsor: Sanofi
Sex: All
Age: 1 - 25
Code: NCT07088068
Phase 3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
for
Plasma Cell Myeloma Refractory
Location: Buffalo NY, Ann Arbor MI, Columbus OH, Atlanta GA
Sponsor: Sanofi
Sex: All
Age: 18+
Code: NCT04643002
Phase 1, Phase 2, Recruiting
Study of ACR-2316 in Specific Advanced Solid Tumors
for
Specific Advanced Solid Tumors
Location: Buffalo NY, Ann Arbor MI, Fairfax VA, The Bronx NY,
Sponsor: Acrivon Therapeutics
Sex: All
Age: 18+
Code: NCT06667141
Phase 1, Phase 2, Recruiting
A Study Evaluating MM-310 in Patients With Solid Tumors
Location: Buffalo NY, Durham NC, Rochester MN, Scottsdale AZ,
Sponsor: Merrimack Pharmaceuticals
Sex: All
Age: 18+
Code: NCT03076372
Phase 1, Recruiting
Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab
for
Atopic Dermatitis
Location: E. Amherst NY, Hamilton, Toronto, Auburn Hills MI,
Sponsor: ASLAN Pharmaceuticals
Sex: All
Age: 18+
Code: NCT05694884
Phase 2, Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
for
Chronic Obstructive Pulmonary Disease
Location: Stoney Creek, Toronto, Ajax, Guelph, Waterloo,
Sponsor: Sanofi
Sex: All
Age: 40 - 70+
Code: NCT07190209
Phase 3, Recruiting
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
for
Hidradenitis Suppurativa
Location: Hamilton, Toronto, New York NY, Johnston RI, Quebec,
Sponsor: Sanofi
Sex: All
Age: 18+
Code: NCT07170917
Phase 2, Recruiting
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
for
Atopic Dermatitis
Location: Hamilton, Markham, Troy MI, Washington D.C. DC,
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 18 - 70+
Code: NCT06947993
Phase 2, Recruiting
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease